Adding a test for human papillomavirus DNA to cervical-cancer screening

New England Journal of Medicine

Volumn 348, Issue 6, 2003, Pages 489-490

  Wright Jr , Thomas C ^b   Schiffman, Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VACCINE; WART VIRUS VACCINE;

CANCER CYTODIAGNOSIS; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CLINICAL TRIAL; DNA DETERMINATION; HEALTH EDUCATION; HUMAN; ONCOGENE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; VACCINATION; VIRUS IDENTIFICATION; VIRUS INFECTION; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0037421596     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMp020178     Document Type: Short Survey

References (3)

1. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
2. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
3. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52.